Symbols / ASMB Stock $27.27 -0.91% Assembly Biosciences, Inc.

Healthcare • Biotechnology • United States • NMS
ASMB (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Jason A. Okazaki J.D.
Exch · Country NMS · United States
Market Cap 433.39M
Enterprise Value 191.06M
Income -6.12M
Sales 72.30M
FCF (ttm) -4.98M
Book/sh 13.04
Cash/sh 15.64
Employees 73
Insider 10d —
IPO Dec 17, 2010
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -11.81
PEG —
P/S 5.99
P/B 2.09
P/C —
EV/EBITDA -15.94
EV/Sales 2.64
Quick Ratio 5.14
Current Ratio 5.22
Debt/Eq 1.27
LT Debt/Eq —
EPS (ttm) -0.55
EPS next Y -2.31
EPS Growth —
Revenue Growth 4.77%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-19
Earnings (prior) 2026-03-19
ROA -4.02%
ROE -5.10%
ROIC —
Gross Margin 10.36%
Oper. Margin 46.62%
Profit Margin -8.47%
Shs Outstand 15.89M
Shs Float 7.49M
Insider Own 32.38%
Instit Own 59.84%
Short Float 14.14%
Short Ratio 18.86
Short Interest 1.53M
52W High 39.71
vs 52W High -31.33%
52W Low 11.01
vs 52W Low 147.68%
Beta 1.16
Impl. Vol. 1.33%
Rel Volume 0.14
Avg Volume 95.93K
Volume 13.32K
Target (mean) $48.75
Tgt Median $46.50
Tgt Low $40.00
Tgt High $62.00
# Analysts 4
Recom None
Prev Close $27.52
Price $27.27
Change -0.91%
About

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$48.75
Mean price target
2. Current target
$27.27
Latest analyst target
3. DCF / Fair value
$-5.64
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$27.27
Low
$40.00
High
$62.00
Mean
$48.75

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-06 main Guggenheim Buy → Buy $43
2026-03-26 reit HC Wainwright & Co. Buy → Buy $50
2025-12-22 reit HC Wainwright & Co. Buy → Buy $50
2025-11-20 main Mizuho Outperform → Outperform $40
2025-10-14 reit HC Wainwright & Co. Buy → Buy $50
2025-09-24 init JMP Securities — → Market Outperform $38
2025-09-08 main Guggenheim Buy → Buy $39
2025-03-25 init Guggenheim — → Buy $31
2025-03-24 reit HC Wainwright & Co. Neutral → Neutral —
2024-12-27 reit HC Wainwright & Co. Neutral → Neutral —
2024-06-20 reit HC Wainwright & Co. — → Neutral —
2024-06-13 reit HC Wainwright & Co. — → Neutral —
2024-04-01 reit HC Wainwright & Co. — → Neutral —
News
RSS: Latest ASMB news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-30 BJORKQUIST JEANETTE M Officer — 328 $26.65 $8,755
2026-03-30 WHITE NICOLE S Officer — 197 $26.65 $5,258
2026-03-27 OKAZAKI JASON A Chief Executive Officer — 94,250 $0.00 $0
2026-03-27 DELANEY WILLIAM E IV Officer — 26,000 $0.00 $0
2026-03-27 BJORKQUIST JEANETTE M Officer — 6,500 $0.00 $0
2026-03-27 WHITE NICOLE S Officer — 26,000 $0.00 $0
2026-03-27 GAGGAR ANUJ Officer — 26,000 $0.00 $0
2025-08-08 GILEAD SCIENCES INC Beneficial Owner of more than 10% of a Class of Security — 2,295,920 $23.97 $55,033,202
2025-06-16 BJORKQUIST JEANETTE M Officer — 300 $0.00 $0
2025-03-31 OKAZAKI JASON A Chief Executive Officer — 355 $9.85 $3,496
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
72.30
+153.52%
28.52
+298.16%
7.16
0.00
Operating Revenue
72.30
+153.52%
28.52
+298.16%
7.16
0.00
Operating Expense
84.42
+14.18%
73.94
+2.97%
71.81
-23.70%
94.11
Research And Development
64.81
+15.88%
55.93
+14.38%
48.90
-30.12%
69.98
Selling General And Administration
19.61
+8.89%
18.01
-21.40%
22.91
-5.08%
24.13
General And Administrative Expense
19.61
+8.89%
18.01
-21.40%
22.91
-5.08%
24.13
Other Gand A
19.61
+8.89%
18.01
-21.40%
22.91
-5.08%
24.13
Total Expenses
84.42
+14.18%
73.94
+2.97%
71.81
-23.70%
94.11
Operating Income
-12.12
+73.32%
-45.42
+29.74%
-64.65
+31.31%
-94.11
Total Operating Income As Reported
-12.12
+73.32%
-45.42
+29.74%
-64.65
+31.31%
-94.11
EBITDA
-11.99
+73.53%
-45.29
+29.45%
-64.20
+31.43%
-93.62
Normalized EBITDA
-11.99
+73.53%
-45.29
+29.45%
-64.20
+31.43%
-93.62
Reconciled Depreciation
0.13
+0.00%
0.13
-71.33%
0.45
-9.64%
0.50
EBIT
-12.12
+73.32%
-45.42
+29.74%
-64.65
+31.31%
-94.11
Total Unusual Items
—
—
—
0.00
Total Unusual Items Excluding Goodwill
—
—
—
0.00
Special Income Charges
—
—
—
0.00
Impairment Of Capital Assets
—
—
—
0.00
Net Income
-6.12
+84.76%
-40.18
+34.38%
-61.23
+34.23%
-93.09
Pretax Income
-6.12
+84.64%
-39.85
+34.89%
-61.20
+34.26%
-93.09
Net Non Operating Interest Income Expense
6.00
+7.59%
5.57
+61.49%
3.45
+237.67%
1.02
Net Interest Income
6.00
+7.59%
5.57
+61.49%
3.45
+237.67%
1.02
Interest Income Non Operating
6.00
+7.59%
5.57
+61.49%
3.45
+237.67%
1.02
Interest Income
6.00
+7.59%
5.57
+61.49%
3.45
+237.67%
1.02
Other Income Expense
—
—
—
—
Tax Provision
0.00
-100.00%
0.33
+900.00%
0.03
0.00
Tax Rate For Calcs
0.00
-100.00%
0.00
+0.00%
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-6.12
+84.76%
-40.18
+34.38%
-61.23
+34.23%
-93.09
Net Income From Continuing Operation Net Minority Interest
-6.12
+84.76%
-40.18
+34.38%
-61.23
+34.23%
-93.09
Net Income From Continuing And Discontinued Operation
-6.12
+84.76%
-40.18
+34.38%
-61.23
+34.23%
-93.09
Net Income Continuous Operations
-6.12
+84.76%
-40.18
+34.38%
-61.23
+34.23%
-93.09
Normalized Income
-6.12
+84.76%
-40.18
+34.38%
-61.23
+34.23%
-93.09
Net Income Common Stockholders
-6.12
+84.76%
-40.18
+34.38%
-61.23
+34.23%
-93.09
Diluted EPS
-0.55
+91.78%
-6.69
+50.00%
-13.38
+41.93%
-23.04
Basic EPS
-0.55
+91.78%
-6.69
+50.00%
-13.38
+41.93%
-23.04
Basic Average Shares
11.21
+86.71%
6.00
+31.18%
4.58
+13.47%
4.03
Diluted Average Shares
11.21
+86.71%
6.00
+31.18%
4.58
+13.47%
4.03
Diluted NI Availto Com Stockholders
-6.12
+84.76%
-40.18
+34.38%
-61.23
+34.23%
-93.09
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
257.59
+116.16%
119.17
-12.90%
136.82
+34.41%
101.79
Current Assets
254.55
+120.38%
115.50
-13.67%
133.79
+37.97%
96.97
Cash Cash Equivalents And Short Term Investments
248.11
+121.37%
112.08
-13.95%
130.25
+42.18%
91.61
Cash And Cash Equivalents
58.45
+52.44%
38.34
+93.26%
19.84
-62.15%
52.42
Other Short Term Investments
189.66
+157.21%
73.73
-33.21%
110.41
+181.71%
39.19
Receivables
0.97
0.00
-100.00%
0.04
-95.44%
0.94
Accounts Receivable
0.97
0.00
-100.00%
0.04
-95.44%
0.94
Prepaid Assets
—
—
—
—
Other Current Assets
5.47
+59.73%
3.42
-2.09%
3.50
-20.76%
4.41
Total Non Current Assets
3.04
-17.03%
3.67
+20.72%
3.04
-37.10%
4.83
Net PPE
2.73
-18.61%
3.35
+23.09%
2.72
-30.83%
3.94
Gross PPE
2.73
-18.61%
3.35
+23.09%
2.72
-51.57%
5.62
Accumulated Depreciation
—
—
-0.21
+87.55%
-1.69
Properties
—
—
0.00
0.00
Machinery Furniture Equipment
—
—
0.24
-65.95%
0.70
Other Properties
2.73
-18.61%
3.35
+23.09%
2.72
-17.38%
3.30
Leases
—
—
0.06
-96.19%
1.63
Investments And Advances
—
—
—
0.00
Other Investments
—
—
—
0.00
Other Non Current Assets
0.31
+0.00%
0.31
+0.00%
0.31
-64.90%
0.89
Total Liabilities Net Minority Interest
50.84
-40.75%
85.81
-10.36%
95.73
+400.40%
19.13
Current Liabilities
48.78
+2.04%
47.80
+21.87%
39.23
+140.70%
16.30
Payables And Accrued Expenses
3.78
+16.72%
3.24
+101.87%
1.61
-76.04%
6.70
Payables
1.17
+100.17%
0.58
+26.90%
0.46
-81.51%
2.49
Accounts Payable
1.17
+100.17%
0.58
+26.90%
0.46
-81.51%
2.49
Current Accrued Expenses
2.61
-1.66%
2.66
+132.05%
1.15
-72.81%
4.21
Pensionand Other Post Retirement Benefit Plans Current
7.52
+16.13%
6.48
+18.13%
5.48
-11.95%
6.23
Current Debt And Capital Lease Obligation
0.57
+23.43%
0.46
-62.21%
1.22
-63.73%
3.36
Current Capital Lease Obligation
0.57
+23.43%
0.46
-62.21%
1.22
-63.73%
3.36
Current Deferred Liabilities
36.90
-1.91%
37.62
+21.69%
30.91
0.00
Current Deferred Revenue
36.90
-1.91%
37.62
+21.69%
30.91
0.00
Total Non Current Liabilities Net Minority Interest
2.06
-94.58%
38.01
-32.73%
56.50
+1893.68%
2.83
Long Term Debt And Capital Lease Obligation
2.06
-21.65%
2.63
+134.22%
1.12
+1010.89%
0.10
Long Term Capital Lease Obligation
2.06
-21.65%
2.63
+134.22%
1.12
+1010.89%
0.10
Non Current Deferred Liabilities
0.00
-100.00%
35.38
-36.12%
55.38
+1926.31%
2.73
Non Current Deferred Revenue
0.00
-100.00%
35.38
-36.12%
55.38
+1926.31%
2.73
Stockholders Equity
206.75
+519.78%
33.36
-18.83%
41.10
-50.28%
82.66
Common Stock Equity
206.75
+519.78%
33.36
-18.83%
41.10
-50.28%
82.66
Capital Stock
0.02
+128.57%
0.01
+40.00%
0.01
+25.00%
0.00
Common Stock
0.02
+128.57%
0.01
+40.00%
0.01
+25.00%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
15.86
+112.62%
7.46
+36.01%
5.48
+34.56%
4.07
Ordinary Shares Number
15.86
+112.62%
7.46
+36.01%
5.48
+34.56%
4.07
Additional Paid In Capital
1,038.82
+20.87%
859.49
+3.94%
826.92
+2.34%
807.98
Retained Earnings
-832.05
-0.74%
-825.92
-5.11%
-785.75
-8.45%
-724.52
Gains Losses Not Affecting Retained Earnings
-0.04
+80.57%
-0.21
-160.49%
-0.08
+89.91%
-0.80
Other Equity Adjustments
-0.04
+80.57%
-0.21
-160.49%
-0.08
+89.91%
-0.80
Total Equity Gross Minority Interest
206.75
+519.78%
33.36
-18.83%
41.10
-50.28%
82.66
Total Capitalization
206.75
+519.78%
33.36
-18.83%
41.10
-50.28%
82.66
Working Capital
205.77
+203.94%
67.70
-28.41%
94.56
+17.22%
80.67
Invested Capital
206.75
+519.78%
33.36
-18.83%
41.10
-50.28%
82.66
Total Debt
2.63
-14.92%
3.09
+31.90%
2.34
-32.41%
3.46
Capital Lease Obligations
2.63
-14.92%
3.09
+31.90%
2.34
-32.41%
3.46
Net Tangible Assets
206.75
+519.78%
33.36
-18.83%
41.10
-50.28%
82.66
Tangible Book Value
206.75
+519.78%
33.36
-18.83%
41.10
-50.28%
82.66
Available For Sale Securities
—
—
—
—
Investmentin Financial Assets
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-41.09
+19.61%
-51.12
-324.76%
22.74
+126.93%
-84.46
Cash Flow From Continuing Operating Activities
-41.09
+19.61%
-51.12
-324.76%
22.74
+126.93%
-84.46
Net Income From Continuing Operations
-6.12
+84.76%
-40.18
+34.38%
-61.23
+34.23%
-93.09
Depreciation Amortization Depletion
0.13
+0.00%
0.13
-71.33%
0.45
-9.64%
0.50
Depreciation And Amortization
0.13
+0.00%
0.13
-71.33%
0.45
-9.64%
0.50
Other Non Cash Items
0.85
-39.94%
1.42
-59.60%
3.51
+0.06%
3.50
Stock Based Compensation
4.68
+49.90%
3.12
-39.05%
5.12
-22.36%
6.59
Asset Impairment Charge
—
—
—
0.00
Deferred Tax
—
—
—
0.00
Deferred Income Tax
—
—
—
0.00
Operating Gains Losses
-0.00
—
0.14
—
Gain Loss On Investment Securities
-0.00
—
—
—
Gain Loss On Sale Of PPE
—
0.00
-100.00%
0.14
0.00
Change In Working Capital
-38.28
-220.38%
-11.95
-115.65%
76.34
+3697.60%
-2.12
Change In Receivables
-0.97
-2365.12%
0.04
-95.23%
0.90
+248.19%
-0.61
Changes In Account Receivables
-0.97
-2365.12%
0.04
-95.23%
0.90
+248.19%
-0.61
Change In Prepaid Assets
-2.04
-2901.37%
0.07
-92.03%
0.92
-31.02%
1.33
Change In Payables And Accrued Expense
1.59
-39.66%
2.63
+145.03%
-5.84
-41814.29%
0.01
Change In Accrued Expense
1.00
-60.06%
2.51
+165.81%
-3.81
-2215.56%
0.18
Change In Payable
0.59
+372.58%
0.12
+106.10%
-2.03
-1124.10%
-0.17
Change In Account Payable
0.59
+372.58%
0.12
+106.10%
-2.03
-1124.10%
-0.17
Change In Other Working Capital
-36.10
-171.52%
-13.29
-115.91%
83.56
—
Change In Other Current Assets
—
0.00
-100.00%
0.58
-29.12%
0.81
Change In Other Current Liabilities
-0.75
+46.36%
-1.40
+62.90%
-3.77
-2.83%
-3.67
Investing Cash Flow
-113.47
-382.46%
40.17
+158.10%
-69.14
-176.28%
90.64
Cash Flow From Continuing Investing Activities
-113.47
-382.46%
40.17
+158.10%
-69.14
-176.28%
90.64
Net PPE Purchase And Sale
-0.07
-135.71%
-0.03
+87.88%
-0.23
-126.47%
-0.10
Purchase Of PPE
-0.07
-135.71%
-0.03
+89.02%
-0.26
-150.00%
-0.10
Sale Of PPE
—
0.00
-100.00%
0.02
0.00
Capital Expenditure
-0.07
-135.71%
-0.03
+89.02%
-0.26
-150.00%
-0.10
Net Investment Purchase And Sale
-113.40
-382.10%
40.20
+158.34%
-68.91
-177.21%
89.24
Purchase Of Investment
-229.83
-153.96%
-90.50
+32.42%
-133.92
-385.52%
-27.58
Sale Of Investment
116.43
-10.92%
130.70
+101.03%
65.02
-44.35%
116.83
Net Business Purchase And Sale
—
—
0.00
-100.00%
1.50
Net Intangibles Purchase And Sale
—
—
—
—
Purchase Of Intangibles
—
—
—
—
Financing Cash Flow
174.67
+493.12%
29.45
+113.12%
13.82
+2150.49%
0.61
Cash Flow From Continuing Financing Activities
174.67
+493.12%
29.45
+113.12%
13.82
+2150.49%
0.61
Net Common Stock Issuance
168.31
+474.54%
29.29
+114.00%
13.69
+4112.00%
0.33
Proceeds From Stock Option Exercised
6.36
+4003.23%
0.15
+20.16%
0.13
-55.36%
0.29
Changes In Cash
20.11
+8.66%
18.50
+156.80%
-32.58
-579.71%
6.79
Beginning Cash Position
38.34
+93.26%
19.84
-62.15%
52.42
+14.88%
45.63
End Cash Position
58.45
+52.44%
38.34
+93.26%
19.84
-62.15%
52.42
Free Cash Flow
-41.16
+19.52%
-51.15
-327.43%
22.49
+126.59%
-84.56
Income Tax Paid Supplemental Data
—
0.42
0.00
—
Amortization Of Securities
-2.35
+35.87%
-3.66
-130.79%
-1.58
-1122.58%
0.15
Common Stock Issuance
168.31
+474.54%
29.29
+114.00%
13.69
+4112.00%
0.33
Issuance Of Capital Stock
168.31
+474.54%
29.29
+114.00%
13.69
+4112.00%
0.33
Sale Of Business
—
—
0.00
-100.00%
1.50
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category